July 13, 2022


Takeaways from Quantum.Tech and BIO conferences


Good morning, Archer recently attended the Quantum.Tech Conference and the BIO International Convention in the US, and I would like to provide you with some key insights from the events.

Quantum.Tech 2022, Boston, USA

The Quantum.Tech Conference is one of the world’s largest in-person quantum technology conferences, covering quantum computing, cryptography, and sensing, and is attended by leading enterprises across several sectors. Archer was the lanyards sponsor for the event.

  • The US National Quantum Initiative Act has led NIST, DoD, NSA, etc., to be heavily involved in quantum technology development with the main task of connecting end users to researchers.
  • A number of Fortune 500 companies are overtly taking steps to adopt quantum technologies, and have upgraded quantum tech from a “nice to have” to a “must have”.
  • Some of the biggest adopters of quantum tech apart from those in the defence sector have been Banks and Telcos, driven by concerns around data security.
  • The global talent shortage for a future quantum workforce is expected to remain a challenge into the foreseeable future.
  • A recurring theme was that future quantum hardware would most likely be application-specific and not based on a single, ubiquitous architecture.

BIO International Convention 2022, San Diego, USA

BIO is one of the largest international biotech conferences. Archer networked with potential partners, delegates from multinational health giants, suppliers, CMOs, CROs, and start-ups, that are relevant to our biochip development.

  • Improvements to current methods of detecting DNA or RNA at very low concentrations with low energy demands for the detection process are of increasing importance globally.
  • With the presence of COVID-19 and the spectre of future outbreaks, Government agencies are advocating for greater collaboration between industry and pathology, with a focus on sovereign advanced manufacturing capability.
  • A strategic shift in traditional test and treatment methodologies is seeing an emergence of platform technologies that could potentially address a growing need for testing convenience and tailored treatment.

Archer’s recent technology progress and growth has allowed the Company to explore opportunities for strategic business relationships on both the east and west coast of America, and I look forward to updating you on our ongoing business development activities.


Dr Mohammad Choucair, FRACI FRSN GAICD
Chief Executive Officer
Archer Materials Limited (ASX:AXE)